20 Online Vets Who Write Prescriptions 🐾📱

Comments (8)

1. My dog has an enlarged heart. She’s a 13-year-old Maltese weighing 4 pounds. Recently, she’s developed a heart-related cough, which I’ve learned is due to the enlargement. It’s been deeply concerning, especially as her breathing has become more congested.

   I took her to a vet, but they wanted to repeat the same tests that have already been done, with an estimate of $900. I’m currently living on Social Security, receiving $1,400 a month, so this cost just isn’t feasible. I’m hoping to get a prescription for a diuretic to help ease her breathing and provide her with some comfort.

   Reply

   1. Given her size, age, and diagnosis of an enlarged heart (likely mitral valve disease, common in small senior breeds like Maltese), the cough and congestion you’re observing are hallmark signs of congestive heart failure (CHF). This occurs when fluid backs up into the lungs due to the heart’s reduced pumping ability, causing labored breathing, wheezing, and persistent coughing—often worse at night or after activity.

      💊 Why a Diuretic Could Help — and When It’s Warranted

      A diuretic, like furosemide (Lasix), can be extremely effective in relieving pulmonary congestion by helping the body expel excess fluid through urination. It’s often the first-line palliative measure in managing CHF. However, because diuretics alter electrolyte balance and kidney function, vets usually require at least basic diagnostics before prescribing—even more so for toy breeds at risk of dehydration or hypokalemia.

      Medication 💊	Purpose 🎯	Risks ⚠️	Monitoring Needed 🔍
      Furosemide (Lasix)	Reduces lung fluid by increasing urination	Dehydration, low potassium, kidney stress	Electrolyte and renal function checks
      Pimobendan (Vetmedin)	Improves heart contraction strength, delays CHF	Possible GI upset, rare arrhythmias	Blood pressure, cardiac re-evaluations
      Enalapril/Benazepril	ACE inhibitor: reduces cardiac workload	Hypotension, fatigue, kidney strain	Periodic bloodwork essential

      🏥 When You Can (and Can’t) Skip Repeat Testing

      While it’s frustrating, some vets require recent diagnostics—like chest X-rays or bloodwork—to prescribe a diuretic safely. However, if you have prior test results within the last 3–6 months, many vets will review those records and potentially proceed with treatment without recharging for everything. Ask your previous vet for copies (email or printed), then call ahead to explain your situation before booking with a new clinic. Some may offer a medication-only consult or a reduced-cost visit.

      💡 Low-Cost Veterinary Resources Worth Exploring

      Several programs and services can help pet parents on fixed incomes. Here are practical, vetted avenues you can try:

      Resource 🧾	How It Helps 💡	Action Steps ✅
      ASPCA Veterinary Assistance	Grants or referrals to reduced-cost care	Visit aspca.org, apply under “Pet Care Financial Aid”
      Local Humane Societies	Often offer low-cost vet clinics or meds	Call nearby shelters for CHF-related help
      Care Credit or Scratchpay	Zero-interest vet financing options	Apply online; some require only soft credit checks
      University Vet Schools	Offer subsidized exams with teaching hospitals	Search for vet schools in your state or region

      📦 Medication Access Without Breaking the Bank

      If your vet agrees to prescribe, ask about furosemide generics, which can be filled at major pharmacies (like Walmart, CVS, or GoodRx-partnered stores) for as little as $4–$15. Also, check if your vet can write a prescription you can fill elsewhere—some markup prices heavily in-house.

      🌬️ At-Home Support While Waiting for Medication

      • Limit exertion: Short potty breaks only; no stairs or long walks.
      • Cool air: Use a fan or A/C to reduce respiratory stress.
      • Elevate her bedding: Prop her head slightly to ease breathing while lying down.
      • Monitor breathing rate: Over 30 breaths per minute at rest = call vet ASAP.

      Symptom 📉	At-Home Relief ⛑️	Urgency 🚨
      Persistent cough, worse when lying down	Elevated rest position, reduced activity	📞 Vet within 24–48 hrs
      Labored or open-mouth breathing	Cool room, calm environment	🚑 Emergency attention needed
      Loss of appetite, weakness	Soft, tempting foods; hand-feed	📅 Vet check recommended

      Always advocate for your pup—you’re doing everything right by asking the hard questions and seeking thoughtful care within your means. Vets who truly understand chronic heart disease in seniors often work *with* you, not against your wallet.

      Reply

      1. My son’s family pit bull is seriously ill. He is 14 years old and hasn’t eaten in three days. He is groaning, seems to be in pain, has significant crust around his eyes, and has foul-smelling gas. While he sometimes gets sick, he normally recovers within a day, but this seems much more serious.

         Reply

         1. This presentation is profoundly concerning and demands immediate emergency veterinary attention. A 14-year-old pit bull showing a triad of prolonged anorexia, overt signs of discomfort, and systemic changes—such as ocular crusting and foul-smelling gastrointestinal output—indicates a multi-system compromise rather than a simple, self-limiting illness.

            Three consecutive days without food in a geriatric dog sets off a dangerous cascade: the body exhausts glucose reserves, rapidly breaks down muscle tissue for fuel, and accelerates dehydration, which thickens the blood and strains the kidneys. This metabolic spiral quickly becomes life-threatening, independent of the primary disease process.

            The groaning is not a subtle sign—it signals substantial pain, likely from deep abdominal discomfort, organ inflammation, or advanced joint disease compounded by systemic illness. In canine medicine, pain vocalization is treated as an urgent marker requiring fast diagnostics and intervention.

            The crusting around the eyes may be secondary to immune system suppression, severe dehydration, or systemic infection, rather than an isolated ocular disorder. When combined with gastrointestinal distress, it raises suspicion of widespread inflammation, toxic buildup, or organ dysfunction.

            The foul-smelling gas strongly suggests a breakdown in normal gastrointestinal flora, possibly due to intestinal obstruction, severe infection, or compromised digestion from pancreatitis, neoplasia, or advanced organ disease. This is a red-flag symptom in a patient already showing multi-system signs.

            Potential emergent differentials for this presentation include:

            • Acute pancreatitis with secondary systemic inflammation.
            • Severe gastrointestinal obstruction or partial blockage causing gas buildup.
            • Rapidly decompensating kidney or liver failure.
            • Systemic infection (sepsis) of abdominal origin.
            • Advanced cancer with metastasis impacting multiple organs.

            Immediate action is essential: This dog should be transported to an emergency veterinary hospital without delay, with a phone call made in transit to alert the team. Intravenous fluids, pain relief, and rapid diagnostic workup (CBC, chemistry panel, urinalysis, imaging) will be necessary to stabilize and identify the cause.

            🚨 Quick Reference – Emergency Indicators in This Case

            Symptom	Why It’s Critical	Possible Causes	Urgency Level
            🍽️ No food intake for 3 days	Triggers metabolic collapse and organ stress	GI blockage, severe illness, pain	Extreme
            😣 Groaning	Indicates significant pain or abdominal crisis	Pancreatitis, obstruction, organ rupture	Extreme
            👁️ Ocular crusting	Possible immune suppression or dehydration	Systemic infection, organ failure	High
            💨 Foul-smelling gas	Suggests severe GI disturbance or infection	Obstruction, bacterial overgrowth, tissue death	Extreme

            Preparation for transport: Gather a brief symptom timeline, list of current medications, and recent medical history. Bring a towel or blanket to keep the dog comfortable, and handle him gently to avoid worsening pain. Maintain a calm voice, as canine stress responses can worsen physiological instability.

            Reply

2. Hello,

   I am reaching out regarding medication for my cat, who may be suffering from dermatitis or another type of skin infection.

   She is an older cat—I’ve had her for over 15 years. While otherwise healthy, she frequently develops red, dried, bloody scabs on her nose, which often bleeds. Occasionally, similar scabs appear on other areas of her body. I believe this may be dermatitis.

   I’m happy to send photos via email if needed. A virtual consultation could be done using a cell phone. You can also reach me on my landline at (772) 777-1786.

   Could you please let me know the cost of a virtual appointment?

   Reply

   1. 🐾 Understanding Your Cat’s Skin Condition

      Based on your description—red, dried scabs on the nose and body, occasional bleeding, and recurrent episodes—your cat may be experiencing feline atopic dermatitis, a chronic inflammatory skin condition triggered by environmental allergens such as pollen, dust mites, or mold spores.

      This condition is characterized by intense itching, leading to scratching, licking, and the development of sores and scabs. It’s common in older cats and can persist throughout their lives.

      However, other conditions like flea allergy dermatitis, food allergies, or bacterial and fungal infections can present similar symptoms. For instance, flea allergy dermatitis is a hypersensitive reaction to flea saliva, causing severe itching and skin lesions. Food allergies can also manifest as skin issues, often requiring dietary trials to identify the offending ingredient. Secondary infections from bacteria or fungi can complicate these conditions, necessitating antimicrobial treatments.

      🧪 Diagnostic Approach

      • Skin Scrapings and Cytology: To detect parasites, bacteria, or yeast.
      • Allergy Testing: Blood tests or intradermal skin tests to identify specific environmental allergens.
      • Elimination Diet Trials: Feeding a hypoallergenic diet for 8–12 weeks to rule out food allergies.
      • Flea Control Assessment: Evaluating the effectiveness of current flea prevention measures.

      💊 Treatment Options

      • Antihistamines: To reduce itching and inflammation.
      • Corticosteroids: For short-term relief of severe inflammation; long-term use is generally avoided due to side effects.
      • Cyclosporine (Atopica®): An immunosuppressive drug effective in managing atopic dermatitis.
      • Fatty Acid Supplements: Omega-3 and omega-6 fatty acids to improve skin health.
      • Topical Therapies: Medicated shampoos or sprays to soothe the skin and control secondary infections.
      • Flea Control: Strict flea prevention using veterinary-recommended products.

      📱 Virtual Veterinary Consultations

      Platform	Cost per Consultation	Services Offered	Notes
      Vetster	Starting at $50	Video consultations, prescriptions, 24/7 availability	Prices vary depending on the veterinarian’s experience and appointment time.
      Chewy’s Connect with a Vet	$19.99	Video consultations, live chat	Free live chat for Chewy customers; video consults not available in Alaska and Hawaii.
      Dutch	Starting at $11/month	Unlimited virtual visits, prescription delivery	Subscription-based model; ideal for chronic conditions.

      📸 Preparing for the Virtual Appointment

      • Photographs: Take clear, close-up photos of the affected areas, including the nose and any lesions on the body.
      • Medical History: Prepare a summary of your cat’s medical history, including previous illnesses, treatments, and any known allergies.
      • Current Medications: List all medications and supplements your cat is currently taking.
      • Behavioral Observations: Note any changes in behavior, appetite, or activity levels.
      • Environmental Factors: Discuss your cat’s living environment, exposure to other animals, outdoor access, and any changes in household products or routines.

      Reply

3. I am writing from Italy regarding my two-year-old male cat, who has recently been diagnosed with hypertrophic cardiomyopathy (HCM). This diagnosis has been devastating for us, and we are doing everything we can to explore all possible treatment options.

   I have learned that in the United States there may be a new medication called Felycin CA1 currently being tested or used, which is not yet available in Europe. I would like to kindly ask if it would be possible, under any circumstances, to obtain a prescription from a licensed veterinarian in the United States in order to try to access this medication for my cat.

   We understand that there may be legal, regulatory, and medical limitations, but we are feeling quite desperate and are simply trying to explore every possible avenue that might help improve or extend his life.

   Any guidance, advice, or information you could provide would mean a great deal to us.

   Thank you very much for your time and consideration

   Reply

   1. First and foremost, your dedication to exploring every pathway for your two-year-old boy is deeply admirable. A diagnosis of hypertrophic cardiomyopathy at such a young age is heartbreaking, but the timing of your inquiry actually coincides with what many veterinary cardiologists are calling the single most significant breakthrough in feline cardiac medicine in decades.

      💙 What Exactly Is Felycin-CA1, and Why Does It Matter?

      Felycin-CA1 is not experimental anymore in the traditional sense. On March 14, 2025, the U.S. Food and Drug Administration granted it conditional approval — making it the very first medication ever sanctioned by any regulatory body worldwide specifically targeting feline hypertrophic cardiomyopathy. The active pharmaceutical ingredient is sirolimus (historically known as rapamycin), formulated into a proprietary delayed-release enteric-coated tablet designed exclusively for cats.

      What distinguishes this therapy from everything that preceded it is the mechanism of action. Traditional HCM management in cats — beta-blockers like atenolol, calcium channel blockers such as diltiazem, or anticoagulants like clopidogrel — addressed symptoms and downstream complications (arrhythmias, clot formation, heart failure). None of them touched the underlying pathology: the progressive thickening of the left ventricular wall itself. Felycin-CA1 operates at a fundamentally different level by inhibiting the mTOR pathway (mechanistic target of rapamycin), which is a master regulator of cell growth, protein synthesis, and cardiac muscle hypertrophy. By suppressing this overactive growth signaling, the drug has demonstrated the ability to halt — and in some cases partially reverse — the actual wall thickening that defines HCM.

      📚 Felycin-CA1 Quick-Reference Profile

      Parameter	Details
      🔬 Active Ingredient	Sirolimus (rapamycin) — delayed-release formulation
      🏠 Developer	TriviumVet (Ireland), now owned by PBI-Gordon Companies (U.S.)
      📋 FDA Status	Conditionally approved — March 14, 2025 (Application #141-604)
      💊 Dosage	0.3 mg/kg orally, once weekly (swallowed whole, with food)
      📦 Tablet Sizes	0.4 mg (orange), 1.2 mg (blue), 2.4 mg (white)
      📅 U.S. Market Availability	Commercially available since late July/August 2025
      🌎 European Availability	Not yet authorized by EMA — regulatory pathway still pending
      🛒 Distributor	PRN Pharmacal (Pegasus Laboratories brand)

      🔬 The Science Behind the Approval: RAPACAT Trial

      The foundation for Felycin-CA1’s conditional approval rests on the RAPACAT trial, a double-blinded, multicentered, randomized, placebo-controlled clinical study published in the Journal of the American Veterinary Medical Association (JAVMA) in July 2023. Led by Dr. Joshua Stern (DVM, PhD, DACVIM — now Associate Dean for Research at NC State College of Veterinary Medicine) alongside collaborators at UC Davis, the trial enrolled 43 client-owned cats with subclinical, nonobstructive HCM.

      Cats were allocated into three groups: low-dose delayed-release rapamycin (0.3 mg/kg weekly), high-dose (0.6 mg/kg weekly), and placebo. Over a 180-day treatment period, the results were striking:

      📈 RAPACAT Trial — Wall Thickness Changes Over 6 Months

      Group	Baseline Maximum Wall Thickness	Day 180 Wall Thickness	Change
      🔴 Placebo	7.99 mm	8.77 mm	+0.78 mm (worsened)
      🟢 Low-dose rapamycin	7.44 mm	7.32 mm	-0.12 mm (improved)
      🟡 High-dose rapamycin	7.50 mm	7.66 mm	+0.16 mm (mild increase)

      The low-dose group achieved statistically significant reductions in maximum ventricular wall thickness compared to placebo (p = 0.01). Crucially, the medication was well tolerated with no significant difference in adverse events across groups. Separate proteomic and transcriptomic analyses from a companion pilot study confirmed anti-inflammatory effects in cardiac tissues and dose-responsive enhancement of autophagy — the cellular housekeeping process that clears damaged proteins and organelles.

      🔍 The HALT Study: What Comes Next

      To pursue full FDA approval, TriviumVet launched the HALT HCM Study in June 2025 — a substantially larger pivotal clinical field trial. This study aims to enroll 300 cats across more than 20 investigator sites throughout the United States, with a 12-month dosing period (double the duration of RAPACAT) and five post-enrollment follow-up visits. Enrollment was reportedly nearing 50% of target as of early 2026, with completion anticipated around 2028. The results of this trial will determine whether Felycin-CA1 transitions from conditional to full regulatory approval.

      ⚠️ Critical Eligibility and Safety Considerations

      This is where your specific situation requires very careful veterinary evaluation. Felycin-CA1 carries a tightly defined label indication:

      • It is approved exclusively for subclinical HCM — meaning cats that have echocardiographic evidence of ventricular hypertrophy but have not yet developed congestive heart failure, arterial thromboembolism, severe left ventricular outflow tract obstruction, or significant arrhythmias.
      • It must not be administered to cats with pre-existing diabetes mellitus (one cat in the RAPACAT trial developed diabetic ketoacidosis, which proved fatal).
      • It must not be used in cats with pre-existing liver disease.
      • Treatment requires liver enzyme monitoring (ALT and AST checked 1-2 months after starting therapy, then every 6-12 months). If transaminase values exceed twice the upper limit of normal, treatment must be discontinued.
      • Safety data does not exist for cats receiving concurrent beta-blockers, corticosteroids, or for cats with kidney disease, hyperthyroidism, or sexually intact status.
      • Drug interactions with cytochrome P-450 3A4 or P-glycoprotein inhibitors (including calcium channel blockers like diltiazem, azole antifungals, and cyclosporine) may increase toxicity risk.

      🚨 Key Contraindications and Monitoring Requirements

      Category	Requirement
      ⛔ Absolute Contraindication	Diabetes mellitus, pre-existing liver disease
      ⚠️ Caution Required	Cats with MDR1 mutation, concurrent P-gp substrate use
      ❌ Not Evaluated	Clinical HCM (heart failure/clots present), cats on beta-blockers or corticosteroids, kidney disease, hyperthyroidism
      👩‍⚕️ Monitoring	Liver enzymes at 1-2 months post-initiation, then every 6-12 months
      😬 Most Common Side Effects	Cardiovascular events (HCM progression-related), lethargy, vomiting, diarrhea, inappetence

      This means that if your cat has already progressed beyond the subclinical stage — showing symptoms of heart failure, clotting episodes, or severe obstruction — Felycin-CA1 may not be appropriate based on current labeling. A board-certified veterinary cardiologist should perform a thorough echocardiographic staging before any decision.

      🌎 The European Access Question: Your Most Pressing Concern

      This is the most complex part of your inquiry, and honesty demands acknowledging the difficulty. Felycin-CA1 is currently authorized only in the United States. TriviumVet’s original website indicated that their product (internally designated TRIV202) was undergoing parallel regulatory review by the European Medicines Agency (EMA), but no European marketing authorization has been granted as of March 2026.

      However, EU veterinary pharmaceutical law does contain a mechanism that could potentially apply to your situation. Under Regulation (EU) 2019/6 — which became applicable on January 28, 2022, and replaced the older Directive 2001/82/EC — the prescribing cascade system permits veterinarians, under strict conditions and their own professional responsibility, to deviate from using only nationally authorized products when no suitable alternative exists and the goal is to prevent unacceptable suffering.

      For non-food-producing animals (companion animals like your cat), the cascade in most EU member states follows a hierarchical structure roughly as follows:

      📜 EU Prescribing Cascade for Companion Animals (Simplified)

      Level	Option
      1️⃣	A veterinary medicine authorized in the same or another EU Member State (same or different species/indication)
      2️⃣	A human medicine authorized in an EU Member State
      3️⃣	An extemporaneously (custom) prepared veterinary medicine per veterinary prescription
      4️⃣	In exceptional cases: a veterinary medicine authorized in a third country (non-EU) for the same species and same indication

      Level 4 is the critical pathway here. Since sirolimus (the active ingredient in Felycin-CA1) does exist as a human-authorized medicine in the EU for transplant immunosuppression, your Italian veterinarian might theoretically explore Level 2 first — using the human formulation off-label. However, the human formulation is fundamentally different from Felycin-CA1’s proprietary delayed-release enteric-coated technology, which was specifically engineered to achieve a particular pharmacokinetic profile in cats that balances mTORC1 inhibition while minimizing mTORC2 disruption. Simply giving a cat the human version of sirolimus at an arbitrary dose could be ineffective or dangerous — the delayed-release mechanism is essential to the drug’s safety profile.

      For accessing the actual branded Felycin-CA1 product from the U.S., your veterinarian in Italy would need to:

      1. Confirm that no suitable authorized alternative exists within the EU (veterinary or human) — which is objectively the case for disease-modifying HCM therapy.
      2. Invoke the cascade at the appropriate level under Italian national implementation of Regulation (EU) 2019/6.
      3. Report the intended import to the relevant Italian authority (likely the Italian Ministry of Health or AIFA/veterinary equivalent).
      4. Obtain the product through a licensed veterinary supply chain — this typically requires coordination between a U.S. veterinarian or pharmacy and the importing Italian veterinarian.

      Practically speaking, this is difficult but not categorically impossible. Each EU member state implements the cascade with slightly different procedural requirements. Italy has its own national rules governing exceptional veterinary imports. Your veterinarian — ideally a veterinary cardiologist affiliated with a university veterinary hospital in Italy — would be the essential advocate in navigating this pathway. University clinics tend to have greater familiarity with compassionate-use and exceptional-import procedures.

      💡 Practical Steps You Can Take Right Now

      🛠️ Actionable Roadmap for Owners Writing from Europe

      Step	Action	Why It Matters
      1	Consult a board-certified veterinary cardiologist in Italy — seek referral to a Diplomate of the European College of Veterinary Internal Medicine (Cardiology)	Only a cardiologist can properly stage your cat’s HCM and determine whether the disease is truly subclinical, which is the required indication for Felycin-CA1
      2	Request full echocardiographic staging including NT-proBNP blood testing and liver panel	These are prerequisite diagnostics under Felycin-CA1’s prescribing information — and they determine eligibility
      3	Ask your cardiologist about the EU prescribing cascade and whether an exceptional import of Felycin-CA1 from the U.S. is feasible under Italian veterinary law	The cardiologist can initiate the regulatory paperwork and communicate with Italian health authorities
      4	Contact TriviumVet directly (www.triviumvet.com) — the Ireland-based developer may have information about European compassionate-use programs or EMA submission timelines	As an Irish company, TriviumVet has European roots and may be closer to EU regulatory approval than publicly announced
      5	Inquire about the HALT HCM Study enrollment — while currently U.S.-based, ask whether any European investigator sites are planned or whether remote participation frameworks exist	Clinical trial participation is sometimes the fastest route to accessing a medication not yet marketed in your jurisdiction
      6	Discuss compounded rapamycin as an interim measure with your cardiologist — some EU compounding pharmacies may be able to prepare a sirolimus formulation under veterinary prescription	This falls under Level 3 of the cascade (extemporaneous preparation), though without the delayed-release technology, efficacy and safety may differ from Felycin-CA1

      💬 A Word About U.S. Prescriptions and Telehealth Caution

      You may encounter online veterinary services or pharmacies in the United States that advertise rapamycin products for cats, sometimes offering remote or telehealth consultations. Exercise extreme caution here. PBI-Gordon Companies (Felycin-CA1’s parent company) has publicly stated that it has no affiliation with any online companies offering rapamycin through telehealth consultations. The branded Felycin-CA1 product uses a very specific delayed-release enteric coating technology — generic or compounded rapamycin products may lack this protection, meaning the active ingredient could be degraded by stomach acid before reaching its intended absorption site, rendering the treatment either ineffective or unpredictably dosed.

      Federal U.S. law restricts Felycin-CA1 to use by or on the order of a licensed veterinarian. Obtaining a legitimate prescription requires an established veterinarian-client-patient relationship, which typically requires a physical examination of the animal. International telemedicine prescriptions for controlled veterinary pharmaceuticals present significant legal grey areas on both the U.S. export side and the Italian import side.

      💗 The Broader Perspective: There Has Never Been More Reason for Hope

      Your cat was diagnosed at a moment when veterinary cardiology is undergoing a genuine paradigm shift. For decades, practitioners had nothing to offer beyond managing the consequences of HCM — waiting for heart failure, clots, or sudden death. The existence of Felycin-CA1 represents the first time a therapy has demonstrated the ability to address the root molecular pathology of the disease.

      Even if immediate access to the branded product proves challenging from Italy, the active ingredient (sirolimus) is a well-characterized pharmaceutical compound with decades of human clinical experience. European veterinary cardiologists are closely watching U.S. developments, and many are already considering how the cascade framework might facilitate access for their patients. The fact that TriviumVet is an Irish company with stated intentions to pursue EU regulatory pathways provides additional grounds for optimism that European availability — whether through EMA authorization or expanded import agreements — is a matter of when, not if.

      📅 Timeline Summary of Key Milestones

      Date	Milestone
      July 2023	RAPACAT trial results published in JAVMA — first evidence of wall thickness reduction
      March 14, 2025	FDA grants conditional approval to Felycin-CA1 — first-ever approved feline HCM medication
      May 2025	PBI-Gordon Companies acquires TriviumVet
      June 17, 2025	Official commercial launch by PRN Pharmacal
      Late July 2025	Felycin-CA1 available through U.S. veterinarians nationwide
      June 2025 – Ongoing	HALT HCM Study enrolling 300 cats (pivotal trial for full FDA approval)
      ~2028 (projected)	HALT Study completion anticipated — data supporting full approval
      TBD	EMA authorization for European market — timeline not yet publicly confirmed

      Your two-year-old cat has youth on his side, which is itself a protective factor in terms of therapeutic response and overall resilience. Pursue that veterinary cardiology referral aggressively, arm yourself with the information above, and know that you are advocating for your cat at precisely the right moment in veterinary medical history. 🐈💙

      Reply